Becotatug vedotin plus sintilimab with chemoradiation for high-risk nasopharyngeal carcinoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a multicenter, randomized, open‑label phase III trial enrolling 266 patients with high‑risk locally advanced nasopharyngeal carcinoma (AJCC 9th edition: anyT N2-3M0 or T4N1M0). Participants are randomized 1:1 to an experimental arm receiving three cycles of neoadjuvant becotatug vedotin plus sintilimab followed by cisplatin‑based concurrent chemoradiotherapy (IMRT) with adjuvant sintilimab, or to a control arm receiving three cycles of gemcitabine plus cisplatin induction followed by the same chemoradiotherapy. The primary endpoint is 3‑year event‑free survival, with secondary endpoints including overall survival, locoregional failure‑free survival, distant metastasis‑free survival, objective response rate, adverse events, and quality of life. The trial also includes biomarker exploratory analyses (for example EGFR expression and PD‑L1 CPS) and predefined dose‑adjustment and toxicity management protocols.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Voluntarily participate in the study and sign the informed consent form in writing.
2. Aged 18-70 years, male or non-pregnant female.
3. Pathologically confirmed as nasopharyngeal non-keratinizing carcinoma (differentiated or undifferentiated type, i.e., WHO type II or III).
4. Staged as anyT N2-3 or T4N1 (9th AJCC/UICC staging) without distant metastasis.
5. ECOG performance status score of 0-1.
6. Hemoglobin (HGB) ≥ 90 g/L, neutrophil count ≥ 1.5×10⁹/L, and platelet (PLT) count ≥ 100×10⁹/L.
7. Liver function: Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 times the upper limit of normal (ULN), and total bilirubin ≤ 1.5 times ULN.
8. Normal renal function: Creatinine clearance rate ≥ 60 ml/min (calculated using the Cockcroft-Gault formula).
9. Sexually active females of childbearing potential must agree to use effective contraceptive measures during treatment and for 1 year after the last administration of the study drug. Males who have sexual relations with females of childbearing potential must also agree to use effective contraceptive measures during treatment and for 1 year after the last administration of the study drug.

Exclusion Criteria:

1. Aged \> 70 years or \< 18 years.
2. Patients with recurrent or distant metastatic nasopharyngeal carcinoma.
3. Pathologically confirmed as keratinizing squamous cell carcinoma (WHO type I).
4. Patients who have previously received radiotherapy or systemic chemotherapy.
5. Positive for hepatitis B surface antigen (HBsAg) with hepatitis B virus DNA \> 1000 copies/mL or 200 IU/mL.
6. Positive for hepatitis C virus antibody (anti-HCV).
7. Patients with active autoimmune diseases, excluding type 1 diabetes mellitus, hypothyroidism controlled by replacement therapy, and skin diseases that do not require systemic treatment (e.g., vitiligo, psoriasis, or alopecia).
8. Patients who received systemic glucocorticoids (equivalent to prednisone \> 10 mg/day) or other immunosuppressive therapy within 28 days prior to signing the informed consent form. Patients who received systemic glucocorticoids equivalent to prednisone ≤ 10 mg/day, inhaled or topical glucocorticoids are eligible for enrollment.
9. Patients with a history of active tuberculosis within the past year; patients with active tuberculosis that has been adequately treated for more than one year are eligible for enrollment. Patients with a history of other malignant tumors (except cured basal cell carcinoma or carcinoma in situ of the cervix).
10. Patients with a history of interstitial lung disease.
11. Patients who received live vaccines within 30 days prior to signing the informed consent form or plan to receive live vaccines in the near future.
12. Pregnant or lactating females.
13. Patients with a history of other malignant tumors within the past 5 years, except carcinoma in situ, adequately treated non-melanoma skin cancer, and papillary thyroid cancer.
14. Patients with known hypersensitivity to any component of gemcitabine, cisplatin, becotatug vedotin, or sintilimab.
15. Patients with known history of HIV infection.
16. Any other conditions deemed by the investigator to potentially affect the patient's ability to sign the informed consent form, cooperate with and participate in the study, or interfere with the interpretation of results, including symptomatic heart failure, unstable angina pectoris, myocardial infarction, active infections requiring systemic treatment, mental illnesses, or family/social factors.

Where it's running

• The First Affiliated Hospital of Guangxi Medical University
  Nanning, Guangxi, China Recruiting

Study contacts

• Principal investigator: Min Kang — First Affiliated Hospital of Guangxi Medical University
• Study coordinator: Min Kang, MD
• Email: kangmin@gxmu.edu.cn
• Phone: +86-771-5356509

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Structured swallowing exercises for nasopharyngeal cancer patients

  This trial tests whether a structured swallowing exercise program improves swallowing and quality of life more than conventional swallowing exercises in adults with nasopharyngeal carcinoma.

  Recruiting Universitas Indonesia · Jakarta Pusat, DKI Jakarta · NCT07909538

• Tafolecimab with chemoimmunotherapy as neoadjuvant treatment for locally advanced colon cancer

  This study tests whether adding tafolecimab to a chemoimmunotherapy regimen helps shrink locally advanced colon cancer before surgery in adults who have pMMR/MSS tumors.

  Recruiting Phase 2 Daping Hospital and the Research Institute of Surgery of the Third Military Medical University · Chongqing, Chongqing Municipality · NCT07840677

• Irreversible Electroporation Added to Targeted Therapy and Immunotherapy for Advanced HCC

  This study tests whether adding irreversible electroporation to lenvatinib and sintilimab can help patients with unresectable advanced hepatocellular carcinoma see bigger tumor shrinkage and become eligible for surgery.

  Recruiting Phase 2 Peking Union Medical College Hospital · Beijing, No. 1 Shuaifuyuan, Dongcheng District, Beijing, China · NCT07832006

• Sintilimab with NALIRIFOX or GP as first-line treatment for metastatic biliary tract cancer

  This study tests whether adding sintilimab to either NALIRIFOX or gemcitabine‑cisplatin can help people with metastatic biliary tract cancer who have not had prior systemic therapy.

  Recruiting Phase 2 The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Nanjing, Jiangsu · NCT07831993

• Dynamic risk prediction for severe blood cell suppression in nasopharyngeal cancer

  This study tests a dynamic risk model to see if it can predict grade 3 or higher anemia, low platelets, or low white blood cells during systemic therapy for adults with nasopharyngeal cancer.

  Recruiting Nanfang Hospital, Southern Medical University · Guangzhou, Guangdong · NCT07819656

• Liposomal irinotecan with 5-FU/LV and sintilimab plus SBRT for unresectable biliary tract cancer

  This trial tests whether combining liposomal irinotecan, 5-FU/LV, and sintilimab, followed by SBRT, can help patients with unresectable locally advanced biliary tract cancer become eligible for surgery or slow disease progression.

  Recruiting Phase 2 The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Nanjing, Jiangsu · NCT07797816

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.